(+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors
Pharmacology Research & Perspectives · 2026
DOI: 10.1002/prp2.70325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2026. Verfasst von Pedro Bans Burtchaell und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB2, Cannabidiol, Cannabinoid Receptor Agonists. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Research Council, Office of the Chief Scientist and Engineer, Investment NSW, NSW Chief Scientist and Engineer.
Abstract (Originalsprache)
(−)‐ trans ‐Cannabidiol ((−)‐CBD) is a principal phytocannabinoid from Cannabis sativa . (−)‐CBD has complex pharmacology but is a relatively weak inhibitor of CB 1 and CB 2 receptor signaling. Cannabidiol has two chiral centres and thus four stereoisomers. (+)‐ trans ‐CBD ((+)‐CBD) has a higher affinity than (−)‐CBD at CB 1 and CB 2 , but its pharmacodynamic effects at these receptors are incompletely described. We examined the activity of (+)‐CBD at human CB 1 and CB 2 receptors using a fluorescence‐based assay of membrane potential in AtT20 cells stably expressing CB 1 or CB 2 receptors. (+)‐CBD produced a rapid, concentration‐dependent hyperpolarization in CB 2 ‐expressing cells ( p EC 50 6.63 ± 0.08) with a maximal effect 90% of the response to CP55940. The CB 2 response was blocked by pertussis toxin pretreatment and competitively inhibited by the CB 2 antagonist AM630 (Schild slope 1.1 ± 0.1). (+)‐CBD was a low‐efficacy, low‐potency CB 1 agonist and inhibited somatostatin‐receptor effects at high concentrations (10–30 μM). (+)‐CBD had no effect on the membrane potential of AtT20 wild‐type cells. In silico modeling of ligand interactions with CB 2 indicated that (+)‐CBD but not (−)‐CBD formed an H‐bond with Ser285, a residue crucial for agonist activation of CB 2 . Our data suggests (+)‐CBD acted as a CB 2 agonist via the orthosteric binding site on the receptor. Synthetic CBD, including (+)‐CBD, has previously been administered in clinical trials, presumably without consideration of its potential CB 2 agonist activity. Given the relative safety of (−)‐CBD in people, (+)‐CBD may be a useful drug to explore CB 2 ‐sensitive disease states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland.
- Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia.
- Nalu Bio, San Francisco, California, USA.
- School of Natural Sciences, Macquarie University, Sydney, New South Wales, Australia.
- School of Biological Sciences, University of Bristol, Bristol, UK.
ORCID-Profile: Marina Junqueira Santiago, Evie J M Clay, Dani Mohnot, Mark Connor
Förderung
- Australian Research Council
- Office of the Chief Scientist and Engineer, Investment NSW
- NSW Chief Scientist and Engineer
Zitieren
APA
Burtchaell, P. B., Santiago, M. J., Wang, C., Hagdoost, M., Clay, E. J. M., Mohnot, D., & Connor, M. (2026). (+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70325
Vancouver
Burtchaell PB, Santiago MJ, Wang C, Hagdoost M, Clay EJM, Mohnot D, et al. (+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors. Pharmacology Research & Perspectives. 2026. doi:10.1002/prp2.70325
BibTeX
@article{Burtchaell2026,
author = {Burtchaell, Pedro Bans and Santiago, Marina Junqueira and Wang, Chenxi and Hagdoost, Mehdi and Clay, Evie J M and Mohnot, Dani and Connor, Mark},
title = {(+)‐Trans‐Cannabidiol Is an Agonist at Human CB 2 Receptors},
journal = {Pharmacology Research & Perspectives},
year = {2026},
doi = {10.1002/prp2.70325}
}
EUVIMED